By Chris Wack
PepGen Inc. shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients.
The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed.
The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated.
PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023.
All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events.
The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 28, 2022 10:00 ET (14:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。